Phibro Animal Health heads into the final stretch before its August 26 earnings with short sellers rebuilding positions and options traders pricing in more downside protection than usual.
The most striking move this week is in short interest. Shorts jumped nearly 12% in a single session on June 25, lifting SI to 6.0% of the free float — the highest level in roughly a month and a notable reversal after a steady grind lower through mid-June. The move is hard to ignore given the context: PAHC fell 31.6% the day after its most recent earnings print in May, and then shed another 38% over the five days that followed. Short sellers appear to be rebuilding ahead of the next quarterly catalyst, now just two months out.
Options positioning tells a similar story. The put/call ratio is running at 1.58, well above its 20-day average of 1.40. That reading is not extreme by historical standards — the 52-week high is 2.23 — but the shift is directionally clear: options traders have added meaningful put exposure over this past week, with the PCR spiking from around 1.02 on June 18 to above 1.58 now. The lending market itself offers no friction for new short positions. Availability is exceptionally loose at around 1,448% — meaning there are roughly 14 shares available to borrow for every one currently shorted — and the cost to borrow is a negligible 0.52%. Nothing in the borrow market is pushing back against this rebuilding short position.
The Street's view is mixed and the most recent data is somewhat dated. Citigroup's Daniel Grosslight, who initiated coverage in mid-April with a Neutral rating and a $62 target, slashed that target to $44 after the May earnings collapse — the most recent analyst action on record, from mid-May. JPMorgan holds an Overweight rating with a $50 target (set in November 2025), while Bank of America maintains an Underperform with a $27 target. The mean price target of $45.60 implies roughly 44% upside from the current price of $31.69, but the wide dispersion between JPM's bull case and BofA's bear case reflects genuine disagreement about whether the business can recover from what was a sharply disappointing quarter. Valuation sits at a trailing P/E near 10x and EV/EBITDA near 7.7x — inexpensive multiples, but potentially a value trap if margin pressure persists. Factor scores back that caution: EPS surprise ranks only in the 38th percentile, and the 12-month forward earnings growth score sits in the bottom fifth of the universe.
One ownership data point worth flagging is CEO Jack Bendheim's activity around the May earnings date. He sold more than $1.2 million in stock across May 5–7, at prices between $47 and $58 — well above where the stock trades now. An independent director, E. Thomas Corcoran, moved in the opposite direction, buying 10,000 shares at $31.77 on May 29, representing a $317,700 investment at prices close to current levels. FMR (Fidelity) added nearly 1.5 million shares in its most recent reported period, a notable build for a stock with a relatively small float. Collectively, the insider picture is split: the CEO lightened up before a difficult quarter, while a director and a major institutional buyer stepped in afterwards.
The closest peer, ZTS, fell 3.3% on the week while ELAN gained just under 1.5%, and MRK outperformed the group with a 13% weekly gain. PAHC's roughly flat week on low volume leaves it lagging the more positive parts of the pharma complex. With the August 26 earnings now the dominant near-term catalyst, how management characterises North American livestock demand and the pace of customer destocking will determine whether the short rebuilding this week proves prescient or premature.
See the live data behind this article on ORTEX.
Open PAHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
